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p300 is an acetyltransferase that targets histone and nonhistone proteins for lysine acetylation. Based on
a p300 structure, Bowers et al. (2010) have conducted an in silico screen for active site small molecule inhib-
itors of p300. We describe this important discovery and its potential therapeutic applications.In human cells, a variety of structurally
unrelated enzymes catalyze the transfer
of acetyl groups from acetyl-coenzyme
A to lysine residues present in acceptor
proteins. As a posttranslational modifica-
tion, acetylation can affect many aspects
of protein function, including protein-
protein interactions, enzymatic activity,
subcellular localization, and protein sta-
bility. Acetylation was first discovered on
histones and has been most studied in
this context where it participates in the
control of gene expression and influences
biological processes as diverse as devel-
opment, inflammation, metabolism, can-
cer, memory, and viral infections. The
acetyltransferase enzymes were called
histone acetyltransferases (HATs) until
recently, when the name was changed
to lysine acetyltransferases (KATs) to
acknowledge a fast growing number of
nonhistone substrates (Allis et al., 2007).
These nonhistone substrates have signifi-
cantly broadened the biological signifi-
cance of HATs or KATs, and form the
molecular basis for their diverse and vital
role in biology.
p300 and its paralog CREB-binding
protein (CBP), now called KAT3A and
KAT3B, have more than 70 defined his-
tone and nonhistone substrates (Wang
et al., 2008). The number is presumably
much larger since the two enzymes are
known to interact with at least 400 cellular
binding partners, making them two of the
most connected proteins in the mamma-
lian protein-protein interaction network
(Bedford et al., 2010). Accordingly, both
enzymes are indispensable during mam-
malian development: mice lacking p300
or CBP die early during development
(E10.5). In humans, mutations in p300 or
CBP are associated with Rubinstein-
Taybi syndrome, a congenital develop-
mental disorder characterized by distinctfacial features, short stature, moderate
to severe learning difficulties, and broad
thumbs and first toes. Chromosomal
translocations involving CBP or p300 are
associated with leukemia, most notably
the t(8;16)(p11;p13) translocation associ-
ated with a subtype of acute myeloid
leukemia. This translocation fuses MOZ,
a distinct HAT/KAT belonging to the
MYST family of acetyltransferases, to the
amino terminus of CBP. Since the fusion
occurs in frame, excessive acetyltrans-
ferase activity of the fusion protein is
credited with its oncogenic potential.
The broad substrate specificity of p300
is correlated with unique structural fea-
tures of its acetyltransferase domain
(Liu et al., 2008). The enzyme lacks
a deep substrate-binding pocket, which
is thought to prohibit formation of a stable
ternary complex between enzyme, acetyl-
coenzyme A, and substrate (Wang et al.,
2008). The enzyme is thought to bind
first to acetyl-coenzyme A and then tran-
siently to the positively charged target
lysine, which dissociates immediately
after acetyl transfer. Substrate binding is
mediated via ‘‘shallow’’ stretches of elec-
tronegative amino acids within the p300
acetyltransferase domain, which mark-
edly differs frommore neutral amino acids
located at the corresponding positions
in other HATs/KATs. This ‘‘hit-and-run’’
mechanism is unique to p300 and CBP,
opening the door to the development of
selective small-molecule inhibitors.
Despite its promiscuous substrate
specificity, the catalytic activity of p300
is highly regulated in cells. The acetyl-
transferase activity is intrinsically weak
but activated after autoacetylation of
a basic activation loop located within
the p300 acetyltransferase domain. This
loop presumably covers the electronega-
tive substrate-binding site under nonace-Chemistry & Biology 17, May 28, 2010tylated conditions but allows substrate
access after autoacetylation (Wang et al.,
2008). Interestingly, p300 autoacetylation
occurs only transiently at gene promoters
where transcription is initiating. Autoace-
tylation is counterbalanced by the activity
of the NAD+-dependent deacetylase
SIRT2,whichmaintainsp300 in adeacety-
lated and enzymatically less active state
(Black et al., 2008). To ensure maximal
enzymatic activation, p300 not only acet-
ylates itself but also its inhibitor SIRT2,
a process that inactivates SIRT2 and
boosts p300 autoacetylation and catalytic
activity (Han et al., 2008) (Figure 1).
Given the broad and important role of
p300 in various biological processes,
there is considerable interest in identifying
p300 inhibitors and in testing their activi-
ties as potential therapeutic agents. Cole
and colleagues reported the first inhibitor
class for p300. A Lys-coenzyme A conju-
gate, designed as a bisubstrate inhibitor,
functions as a potent (Ki 20 nM) and
selective p300 inhibitor (Lau et al., 2000).
Another coenzyme A conjugate with
a histone H3 peptide was shown to func-
tion as a selective PCAF inhibitor (Lau
et al., 2000). Lys-CoA was made cell
permeable by attachment to a Tat peptide
and was used in a number of studies, but
its complexity has limited its further phar-
macological development. Subsequent
reports identified several natural products
as p300 inhibitors including curcumin
(isolated from turmeric), garcinol (garlic),
and anacardic acid (cashew nut). Curcu-
min is a polyphenolic compound that
has been used as a component of Indian
Ayurvedic medicine. In vitro and animal
studies have suggested that curcumin
may have antitumor, antioxidant, antiar-
thritic, and anti-inflammatory properties.
High throughput screens also led to the
identification of several synthetic smallª2010 Elsevier Ltd All rights reserved 417
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Figure 1. p300 Regulation and Its Nonhistone Substrates
p300 autoacetylation enhances its acetyltransferase activity. The NAD-depen-
dent sirtuin SIRT2 deacetylates p300 and inactivates it, while p300 acetylation
of SIRT2 inhibits its deacetylase activity. Several nonhistone substrates of
p300 and their possible therapeutic implications are shown.
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but their selectivity andmech-
anisms of inhibition have not
been fully elucidated. These
limitations have restricted the
exploration of the therapeutic
potential of p300 as a drug
target.
Bowers et al. (2010) now
report the identification of
a novel p300 inhibitor. They
used the structure of the
p300 HAT domain com-
plexed with Lys-CoA for
in silico screening (Liu et al.,
2008). A library of 500,000
commercially available com-
pounds was computationally
docked into the Lys-CoA
binding pocket. Out of 194initial leads, 3 compounds were found to
be relatively potent p300 inhibitors (Ki <
5 mM). One of these compounds, C646,
a pyrazolone-furan, was highly selective
against p300 in comparison with six other
HATs and was shown to function as
a reversible linear competitive inhibitor of
p300 versus acetyl-coA (Ki = 400 nM).
Mutation of Trp1466 (to Phe) in the cata-
lytic active site of p300 induced a 7-fold
decrease in affinity for C646, supporting
the model that this inhibitor binds directly
to the catalytic pocket of p300 and
competes with its substrate.
Importantly, the p300 inhibitor C646
suppressed histone H3 and H4 acetyla-
tion in mouse fibroblast cell lines and sup-
pressed the growth ofmelanoma and lung
cancer cell lines in vitro. In contrast, a non-
transformedmurine cell line (NIH 3T3) was
not inhibited by C646. Inhibition of trans-
formed cell line growth was associated
with a decreased histone acetylation
and with a G1/S cell cycle arrest, con-
sistent with p300 inhibition. These obser-
vations support the model that p300418 Chemistry & Biology 17, May 28, 2010 ªinhibition represents a novel and prom-
ising therapeutic target for cancer.
Much remains to be learned about
p300. Although p300 and CBP share
extensive sequence homology, they are
not identical and have distinct biological
activities. Future efforts in this field could
focus on the development of p300 versus
CBP selective inhibitors. In addition,
several biological functions of p300 have
been described that are independent
of its acetyltransferase activity. For
example, mutations within the p300 ace-
tyltransferase domain have little effect
on hematopoiesis. Notably, CBP and
p300 both possess E4 polyubiquitin ligase
activities, whichmay account for the acet-
ylation-independent functions of these
proteins (Grossman et al., 2003; Shi
et al., 2009).
The development of selective p300
inhibitors represents a milestone in the
field of protein acetylation.While inhibitors
of histone/protein deacetylases (HDAC/
KDAC) have been the focus of intense
study (two HDAC inhibitors were recently2010 Elsevier Ltd All rights reservedapproved by the Food and
Drug Administration and are
in the clinic), the field of
HAT/KAT inhibitors has been
somewhat lagging. The dis-
covery of selective new p300
inhibitors should allow for
more extensive and definitive
testing of its potential as a
therapeutic target in a num-
ber of important pathological
conditions.REFERENCES
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